Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326)

Autor:	B. Valenta-Singer, W. B. Knowlton, Brigitt E. Abbuehl, Tomasz Urasiński, J. L. Lamas, L. Rusen, Margit Serban, F. G. Perina, Borislava G. Pavlova, M. H. Solano Trujillo, Myungshin Oh, Oleksandra Stasyshyn
Rok vydání:	2014
Předmět:	Adult Male medicine.medical_specialty Adolescent Hemorrhage Haemophilia Hemophilia B Comparative evaluation Factor IX Young Adult Internal medicine medicine Humans Haemophilia B Prospective Studies Child Adverse effect Blood Coagulation Genetics (clinical) Bleeding episodes Cross-Over Studies Blood Coagulation Factor Inhibitors Coagulants Drug Substitution business.industry Incidence Incidence (epidemiology) Hematology General Medicine Middle Aged medicine.disease Recombinant Proteins Dysgeusia Surgery Female medicine.symptom Previously treated business
Zdroj:	Haemophilia. 20:674-681
ISSN:	1351-8216
Popis:	The ability to switch between coagulation factors safely is of common interest to haemophilia patients and treating physicians. This is the first formal prospective comparative evaluation of safety, efficacy and incremental recovery of a plasma-derived FIX (pdFIX) and a recombinant FIX (rFIX) in the same haemophilia B patients following a switch from pdFIX Immunine® to a recently developed rFIX Bax326 product. Patients (aged
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04cd23a2b42785abbf9ccdf95b441655 https://doi.org/10.1111/hae.12444 Zobrazit plný text záznamu Plný text ve formátu PDF